Development of mavoglurant and its potential for the treatment of fragile X syndrome

Baltazar Gomez-Mancilla, Elizabeth Berry-Kravis, Randi J Hagerman, Florian Von Raison, George Apostol, Mike Ufer, Fabrizio Gasparini, Sébastien Jacquemont

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Introduction: Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability. With no curative treatment available, current therapeutic approaches are aimed at symptom management. FXS is caused by silencing the FMR1 gene, which encodes FMRP; as loss of FMRP leads to the development of symptoms associated with FXS. Areas covered: In this evaluation, the authors examine the role of the metabotropic glutamate receptor 5 (mGluR5) in the pathophysiology of FXS, and its suitability as a target for rescuing the disease state. Furthermore, the authors review the evidence from preclinical studies of pharmacological interventions targeting mGluR5 in FXS. Lastly, the authors assess the findings from clinical studies in FXS, in particular the use of the Aberrant Behavior Checklist-Community Edition (ABC-C) and the recently developed ABC-C for FXS scale, as clinical endpoints to assess disease modification in this patient population. Expert opinion: There is cautious optimism for the successful treatment of the core behavioral and cognitive symptoms of FXS based on preclinical data in animal models and early studies in humans. However, the association between mGluR5-heightened responsiveness and the clinical phenotype in humans remains to be demonstrated. Many questions regarding the optimal treatment and outcome measures of FXS remain unanswered.

Original languageEnglish (US)
Pages (from-to)125-134
Number of pages10
JournalExpert Opinion on Investigational Drugs
Issue number1
StatePublished - Jan 2014


  • Aberrant Behavior Checklist
  • FMRP
  • Fragile X syndrome
  • FXS
  • Mavoglurant
  • MGluR5

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Development of mavoglurant and its potential for the treatment of fragile X syndrome'. Together they form a unique fingerprint.

Cite this